Join the 'Atrial Flutter' group to help and get support from people like you. How it works
Atrial Flutter Blog
| Tweet |
Multaq Sanctioned for Heart Rhythm Disorders
Posted 2 Jul 2009 by Drugs.com
THURSDAY, July 2 – Multaq (dronedarone) tablets have been approved by the U.S. Food and Drug Administration to promote a normal heart rhythm in people with atrial fibrillation or atrial flutter. These conditions cause the heart to beat too quickly and can prevent it from pumping blood correctly. The drug's label, however, will contain a "black box" warning that the medication could cause deadly reactions in people with recent severe heart failure, the agency said Thursday in a news release. In clinical testing involving more than 4,000 people, Multaq lowered the rates of cardiac hospitalization or death from any cause by 24 percent, compared to an inactive placebo, the FDA said. The most common side effects were diarrhea, nausea, vomiting, fatigue and weakness. Multaq is produced by French drug maker Sanofi-Aventis. More information The FDA has more about this approval. Read more
Related support groups: Atrial Fibrillation, Atrial Flutter
Ask a Question
Further Information
Related Condition Support Groups
Related Drug Support Groups
diltiazem, Cardizem, flecainide, sotalol, Cardizem CD, Multaq, Cartia XT, propafenone, Tambocor, view more... Rythmol, Cardizem LA, dronedarone, Tiazac, Rythmol SR, esmolol, Diltia XT, Dilacor XR, Sotalol Hydrochloride AF, Betapace AF, Diltzac, Dilt-XR, ibutilide, Corvert, Brevibloc, Cardizem SR, Cardizem Monovial